Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cytogenetic and clinical marks for defining high-risk myeloma in the context of bortezomib treatment.

Experimental hematology - 1 Mar 2015

An Gang, Acharya Chirag, Deng Shuhui, Yi Shuhua, Xu Yan, Qin Xiaoqi, Sui Weiwei, Li Zengjun, Shi Lihui, Zang Meirong, Feng Xiaoyan, Hao Mu, Zou Dehui, Zhao Yaozhong, Qi Junyuan, Cheng Tao, Ru Kun, Wang Jianxiang, Tai Yu-Tzu, Qiu Lugui

Abstract excerpt

Multiple myeloma (MM) is a heterogeneous disease, and the benefit from bortezomib treatment is not uniform among all patients subgroups. Currently, little information is available to predict patients response to bortezomib treatment. In this study, we aimed to identify patients benefiting minimally from bortezomib as part of first-line therapy and to define high-risk MM in the context of bortezomib treatment. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Boronic Acids
Share to Bortezomib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to L-Lactate Dehydrogenase

Share to Multiple Myeloma

Share to Multivariate Analysis

Share to Pyrazines

Share to Survival Analysis

Share to Thalidomide

Source

Identifiers

PMID: 25462022
DOI: 10.1016/j.exphem.2014.11.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytogenetic and clinical marks for defining high-risk myeloma in the context of bortezomib treatment.PMID 25462022Read ↗

A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy.Semantic proximity Read ↗

Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysisSemantic proximity Read ↗

Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literatureSemantic proximity Read ↗

Minor clone of del(17p) provides a reservoir for relapse in multiple myelomaSemantic proximity Read ↗

Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factorSemantic proximity Read ↗

High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes.Semantic proximity Read ↗

Impact of High-Risk Cytogenetics and Achievement of Molecular Remission on Long-Term Freedom from Disease after Autologous–Allogeneic Tandem Transplantation in Patients with Multiple MyelomaSemantic proximity Read ↗

Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Societe Francaise de Greffe de Moelle et de Therapie CellulaireSemantic proximity Read ↗

del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma.Semantic proximity Read ↗

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomibSemantic proximity Read ↗

Hematopoietic Score for the Prognostic Evaluation of Multiple Myeloma Patients Undergoing First-Line Treatment With A Bortezomib-Based RegimenSemantic proximity Read ↗

Increased LDH Remains a Crucial Prognostic Factor in Patients with Multiple Myeloma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.